MeSH term
Frequency | Condition_Probility | Adult | 12 | 0.0 |
Alleles | 6 | 0.0 |
Female | 20 | 0.0 |
Gene Frequency | 7 | 0.0 |
Humans | 38 | 0.0 |
Interferon Type II/*genetics | 11 | 21.0 |
Interleukin-10/*genetics | 2 | 4.0 |
Italy | 2 | 0.0 |
Male | 20 | 0.0 |
Middle Aged | 10 | 0.0 |
*Polymorphism, Genetic | 7 | 0.0 |
Research Support, Non-U.S. Gov't | 26 | 0.0 |
Animals | 8 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Comparative Study | 5 | 0.0 |
Hamsters | 3 | 0.0 |
Mice | 6 | 0.0 |
Molecular Sequence Data | 5 | 0.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Polymerase Chain Reaction | 3 | 0.0 |
Adolescent | 6 | 0.0 |
Case-Control Studies | 7 | 0.0 |
Child | 6 | 0.0 |
Child, Preschool | 4 | 0.0 |
Infant | 2 | 0.0 |
Introns | 2 | 0.0 |
Cohort Studies | 2 | 0.0 |
Dinucleotide Repeats | 2 | 2.0 |
Family Health | 2 | 0.0 |
Finland | 2 | 0.0 |
Genotype | 6 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Multiple Sclerosis/*genetics | 2 | 2.0 |
Prognosis | 2 | 0.0 |
Aged | 5 | 0.0 |
DNA/genetics | 2 | 0.0 |
Germany | 2 | 0.0 |
Interferon Type II/genetics | 3 | 3.0 |
Polymorphism, Genetic | 3 | 0.0 |
Gene Expression | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 2 | 0.0 |
Microsatellite Repeats | 2 | 0.0 |
Risk Factors | 3 | 0.0 |
Disease Progression | 2 | 0.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Th1 Cells/*immunology | 2 | 1.0 |
Cells, Cultured | 4 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 4 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Cell Line | 2 | 0.0 |
Base Sequence | 5 | 0.0 |
Hybrid Cells | 2 | 0.0 |
DNA Primers | 2 | 0.0 |
Japan | 3 | 0.0 |
*Chromosomes, Human, Pair 12 | 3 | 1.0 |
Trans-Activators/genetics | 2 | 0.0 |
Antigens, CD/*biosynthesis | 2 | 1.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
